• Mashup Score: 0
    ITM and Clovis Oncology Announce Lutetium-177 Clinical Supply Agreement - 4 year(s) ago

    ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Clovis Oncology’s Targeted Radionuclide Therapy candidate FAP-2286Munich, Germany and BOULDER, Colo., 19 October, 2021 – ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, and Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the signing of a clinical supply…

    Source: itm-radiopharma.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_Radiopharma
      ITM_Radiopharma

      Today we announced our clinical supply agreement with Clovis Oncology to provide our partner with our therapeutic radioisotope, n.c.a. Lutetium-177, for the clinical development of its fibroblast activation protein (FAP)-targeting therapeutic candidate. https://t.co/bg7TqmGHBU https://t.co/KAmFUXcq28

  • Mashup Score: 2
    ITM Announces Completion of Conversion into SE - 4 year(s) ago

    ITM, a leading radiopharmaceutical biotech company, announced today with the registration in the Commercial Register of the District Court of Munich, the completion of its conversion from a German stock corporation (Aktiengesellschaft, “AG”) into a European company (Societas Europaea, “SE”). As of September 21, 2021, ITM is operating under the registered name ITM Isotope Technologies Munich SE…

    Source: itm-radiopharma.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_AG
      ITM_AG

      Today we announced the completion of our conversion into an SE. The transition represents the next logical step in our growth trajectory and further suits ITM’s international position. Please visit: https://t.co/LiiijNROAn https://t.co/13RShqLMqd

  • Mashup Score: 0
    ITM to Host Virtual Symposium at the ESMO Congress 2021 with Key Neuroendocrine Tumor Experts on September 17, 2021 - 4 year(s) ago

    ITM AG, a leading radiopharmaceutical company, today announced that it will host a virtual industry satellite symposium titled, “A Global Perspective on the Management of Neuroendocrine Tumors – the Evolving Role of Targeted Radionuclide Diagnostics and Therapy” at the European Society of Medical Oncology (ESMO) Congress 2021. The symposium will feature renowned key opinion leaders in the field…

    Source: itm-radiopharma.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_AG
      ITM_AG

      ITM to host Virtual Symposium at ESMO 2021 with Key NET Experts on Sep 17, 2021. The symposium containing critical discussions addressing the changes in treatment and diagnosis of NETs will be held on Friday, Sep 17th, 2021, from 10:30am - 12:00pm CEST https://t.co/Gf7I2B4quX https://t.co/S4AiwBVfDM

  • Mashup Score: 2
    Precision Oncology Pipeline - 4 year(s) ago

    ITM is developing a leading 3rd generation radioisotope platform in the field of Precision Oncology with several blockbuster Theranostics.

    Source: itm-radiopharma.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_AG
      ITM_AG

      Happy to support tomorrow's 18th transregional NET Day #symposium in Magdeburg. The event features presentations from renowned experts on the diagnostics and therapy of NETs. Learn more about our R&D in the field of Targeted Radionuclide Therapy for NETs: https://t.co/G5jwBMwvk3 https://t.co/4hWtAqrLKv

  • Mashup Score: 0
    Precision Oncology Pipeline - 4 year(s) ago

    ITM is developing a leading 3rd generation radioisotope platform in the field of Precision Oncology with several blockbuster Theranostics.

    Source: itm-radiopharma.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_AG
      ITM_AG

      Happy to support tomorrows’ 18th transregional NET Day #symposium in Magdeburg. The event features presentations from renowned experts on the diagnostics & therapy of NETs. Learn more about our R&D in the field of Targeted Radionuclide Therapy for NETs: https://t.co/G5jwBMwvk3 https://t.co/hWGLgM5Zdx

  • Mashup Score: 1
    Passion for Precision - 4 year(s) ago

    ITM Isotopen Technologien München AG and it’s subsidiaries develop, produce and supply innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals.

    Source: itm-radiopharma.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_AG
      ITM_AG

      #MeetTheTeam: Dr Thomas Gottlieb, ITM’s Head of Global Sales, Product Management & Marketing for Radiopharmaceuticals. He has keen skills in #MedicalSales & #ProductManagement and is highly motivated to bring our Therapy to hospitals worldwide. Learn more: https://t.co/I8pydrJzHv https://t.co/BB1eBEx1TU

  • Mashup Score: 0
    Passion for Precision - 4 year(s) ago

    ITM Isotopen Technologien München AG and it’s subsidiaries develop, produce and supply innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals.

    Source: itm-radiopharma.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_AG
      ITM_AG

      #MeetTheTeam: Next in our series is Ursula Weiß, ITM’s assistant in regulatory & clinical development. Ursula appreciates ITM’s commitment to #PrecisionOncoloy and #teamwork & ITM’s pipeline of #radionuclide treatment options. Learn about our approach at: https://t.co/PaXRK9VmbD https://t.co/HfOiA6gmcr

  • Mashup Score: 3
    Passion for Precision - 4 year(s) ago

    ITM Isotopen Technologien München AG and it’s subsidiaries develop, produce and supply innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals.

    Source: itm-radiopharma.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_AG
      ITM_AG

      #MeetTheTeam: Next in our series we introduce, Sabrina Petosic, ITM’s Deputy Head of Production. Sabrina is passionate about working in #biotech & takes pride in promoting our innovative #PrecisionOncology pipeline. Learn more about our team: https://t.co/PaXRK9VmbD https://t.co/3aC7UclrMN

Load More